GLP-1 Microdosing: What the Evidence Actually Says

Microdosing versus reduced-dose maintenance

These get conflated constantly, and the conflation is usually deliberate because it lets a commercial proposition borrow the credibility of a research question.

Reduced-dose maintenance means a prescriber lowers a dose that has already produced a result, under monitoring, after a plateau. SURMOUNT-MAINTAIN tested exactly this and found 5 mg maintained 16.6% bodyweight reduction against 21.9% on the maximum tolerated dose and 9.9% on placebo. It is a real, evidenced strategy.

Microdosing means starting below the studied range in the hope of a proportional effect at lower cost. There is no randomised evidence for it at all. One lowers a dose that worked; the other never establishes that the dose works.

What the dose-response curve actually shows

SURMOUNT-1 recorded mean weight reduction of about 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg over 72 weeks. That is a real dose-response, and it flattens noticeably at the top — the increment from 10 mg to 15 mg is roughly a quarter of the increment from 5 mg to 10 mg.

People sometimes read that flattening as evidence that less drug works nearly as well, and extend the line downward. That extrapolation is not supported. Curves flatten at the top of a studied range; nothing about that behaviour predicts what happens below the bottom of it.

The 2.5 mg dose sits below the studied treatment range for a specific reason: it exists to build tolerance before therapeutic exposure. Its purpose is not weight reduction, and it was not tested as a treatment arm.

Is it safer?

Plausibly, and untested. Lower exposure would be expected to reduce gastrointestinal effects, which are dose- and change-related. That is a reasonable pharmacological inference.

But 'fewer side effects' is only meaningful alongside 'how much effect'. A dose low enough to avoid nausea entirely may also be low enough to do very little, and no trial has measured where that trade-off sits. Presenting the tolerability half without the efficacy half is the core of the marketing.

There is a second, subtler risk. Someone on an unmeasured low dose who sees minimal results may conclude the drug class does not work for them, and stop — when a properly titrated dose under a prescriber might have worked.

Why is it offered at all?

The economics are straightforward. A lower dose costs the provider less in drug while the programme fee, consultation and shipping stay roughly the same. Margin improves and the advertised headline falls, which is an attractive combination in a price-sensitive market.

That does not make anyone offering it dishonest. It does mean the incentive runs toward promoting a strategy with no randomised evidence, and a reader should weigh marketing claims accordingly.

The tell is usually in what gets quoted. Material promoting microdosing almost always cites weight-loss figures — and those figures, without exception, come from trials of the full studied doses.

What to ask if you are considering it

Ask what dose specifically, and what evidence exists for that dose in weight management. If the answer cites SURMOUNT figures, those describe 5, 10 and 15 mg.

Ask what the plan is if it does not work — whether escalation to a studied dose is available and at what price, since discovering that the effective dose costs substantially more changes the original value proposition.

And ask who is monitoring. A prescriber deliberately using a low dose with a monitoring plan and an escalation path is doing something different from a programme selling a low dose as a product. This site publishes no dosing schedules at any dose; that decision belongs with your prescriber.

Frequently asked questions

Sources

• SURMOUNT-1 — New England Journal of Medicine
• SURMOUNT-MAINTAIN — The Lancet

Every clinical claim above links to a primary source: an FDA record, a peer-reviewed publication with DOI or PMID, or a ClinicalTrials.gov registration. Where a figure could not be verified against a primary source, it is labelled rather than asserted.